Review Article
Mycobacterium avium Complex Pulmonary Disease in Immunocompetent Patients
Abstract
Mycobacterium avium complex is becoming increasingly recognized as one of the most common mycobacterial pathogens in humans. It is rapidly becoming a significant cause of pulmonary disease even in those with an intact immunity. In 1997, the American Thoracic Society published recommendations for the diagnosis and treatment of nontuberculous mycobacteria. On the basis of the authors' clinical experience of the myriad presentations of pulmonary Mycobacterium avium complex disease in an immunocompetent host, a clinical classification is proposed. The current data are summarized, and a practical approach to management of the various pulmonary forms of the disease is provided.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Aronson T, Holtzman A, Glover N, et al. Comparison of large restriction fragments of Mycobacterium avium isolates recovered from AIDS and non-AIDS patients with those of isolates from potable water. J Clin Microbiol 1999;37:1008–1012.
2. Yajko DM, Chin DP, Gonzalez PC, et al. Mycobacterium avium complex in water, food, and soil samples collected from the environment of HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:176–182.
3. von Reyn CF, Maslow JN, Barber TW, et al. Persistent colonization of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 1994;343:1137–1141.
4. Meissner G, Anz W. Sources of Mycobacterium avium-complex infection resulting in human disease.Am Rev Respir Dis 1977;116:1057.
5. Kubo K, Yamazaki Y, Hanaoka M, et al. Analysis of HLA antigens in Mycobacterium avium-intracellulare pulmonary infection. Am J Respir Crit Care Med 2000;161:1368–1371.
6. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:s1–s25.
7. Iseman MD. Medical management of pulmonary disease caused by Mycobacterium avium complex.Clin Chest Med 2002;23:633–641.
8. Ahn CH, McLarty JW, Ahn SS, et al. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis 1982;125:388–391.
9. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. Chest 1992;101:1605.
10. Chalernskulrat W, Gilby JG, Donahue JF. Nontuberculous mycobacteria in women, young and old.Clin Chest Med 2002;23:675–686.
11. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989;321:863–868.
12. Yamazaki Y, Kubo K, Takamizawa A, et al. Markers indicating deterioration of Mycobacterium avium-intracellulare infection. Am J Resp Crit Car Med 1999;160:1851–1855.
13. Oliver A, Maiz L, Canton R, et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001;32:1298–1303.
14. Murras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002;23:553–567.
15. Nick JA. Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med 2003;24:693–702.
16. Wittram C, Weisbrod GL. Mycobacterium avium complex lung disease in immunocompetent patients: Radiography-CT correlation. Br J Rad 2002;75:340–344.
17. Iseman MD, Buschman DL, Ackersom LM. Pectus excavatum and scoliosis: Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis1991;144:914–916.
18. Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Resp Crit Care Med1997;155:2041–2046.
19. Griffith DE, Brown BA, Murphy DT, et al. Initial (6 month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus negative patients. J Infect Dis 1998;178:121–126.
20. Griffith DE, Brown BA, Cigielski P, et al. Early results (at 6 months) with intermittent clarithromycin-inducing regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288–292.
21. Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: An update.Arch Intern Med 2002;162:985–991.
22. Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions. Arch Intern Med1997;157:2453–2458.
23. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124:1482–1486.
24. Dautzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995;107:1035–1040.
25. Wallace RJ, Zhang Y, Brown-Elliot BA, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002;186:266–273.
26. Horsburgh CR, Mason UG, Heifits LB, et al. Response to therapy of pulmonary Mycobacterium avium intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis1987;135:418–421.
27. Heifits LB, Iseman MD. Choice of antimicrobial agents for M avium disease based on quantitative tests of drug susceptibility. N Engl J Med 1990;323:419–420.
28. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother1999;44:393–395.
29. Bermudez LE, Inderlied CB, Kolonoski P, et al. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.Antimicrob Agents Chemother 2001;45:217–222.
30. Bermudez LE, Kolonoski P, Petrofsky M, et al. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis 2003;187:1977–1980.
31. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fiber-optic bronchoscopy. J Antimicrob Chemother 1999;44:835–838.
32. Kemper CA, Havlir D, Bartok AE, et al. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994;170:157–164.
33. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazomine for the treatment of Mycobacterium avium complex disease in patients with HIV infection. AIDS1997;11:311–317.
34. Bermudez LE, Kolonoski P, Wu M, et al. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob Agents Chemother 1999;43:1870–1874.
35. Wu M, Aralor P, Nash K, et al. Linezolid, a new oxazolidinone, has activity in vitro and in macrophage culture system against Mycobacterium avium complex (MAC) [abstract E-143]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 September 24–27 (San Diego, CA).
36. Nannini EC, Keating M, Binstock P, et al. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect2002;44:201–203.
37. Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother 1988;32:1131–1136.
38. Rastogi N, Bauriaud RM, Bourgoin A, et al. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex.Antimicrob Agents Chemother 1995;39:638–644.
39. Research Committee of the BTS Pulmonary Disease caused by Mycobacterium Avium-intracellulare in HIV-negative patients. Five-year follow-up of patients receiving standardized treatment. Int J Tuberc Lung Dis 2002;6:628–634.
40. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma: A preliminary report. N Engl J Med 1994;330:1348–1355.
41. Yuji S, Yutsuki N, Keiichiso T, et al. Surgery for Mycobacterium avium lung disease in the clarithromycin era. Eur J Cardiothor Surg 2002;21:314–318.
42. Khoor A, Leslie KO, Tazelaar HD, et al. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol 2001;115:755–762.
43. Kahana LM, Kay JM, Yakrus MA, et al. Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure. Chest 1997;111:242–245.
44. Embil J, Warren P, Yakrus M, et al. Pulmonary illness associated with exposure to Mycobacterium avium complex in hot tub water: Hypersensitivity pneumonitis or infection? Chest 1997;111:813–816.
